Transfusion-Transmitted Cytomegalovirus Prevention in Neonates
Status:
Completed
Trial end date:
1988-06-01
Target enrollment:
Participant gender:
Summary
To evaluate the capacity of intravenously administered cytomegalovirus (CMV)-immune globin
(CMVIG) to immunize high risk premature infants against CMV infections.